Cytek BioSciences Inc
CTKB
Get informed when a big investor buys or sells
+ FollowMarket Cap$726.6M
Close$
$0.21
96.2% downside
Current Fair Value
96.2% downsideOvervalued by 96.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $726.60 Million |
|---|---|
| Enterprise Value | $708.42 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.52 |
| Beta | 1.16 |
| Outstanding Shares | 129,460,518 |
Return
| Return on Equity | -25.03% |
|---|---|
| Return on Assets | -18.03% |
| Return on Invested Capital | -11.67% |
Valuation & Multiples
| P/E Ratio | -8.97 |
|---|---|
| PEG | -7.62 |
| Price to Sales | 5.59 |
| Price to Book Ratio | 2.8 |
| Enterprise Value to Revenue | 3.43 |
| Enterprise Value to EBIT | -16.74 |
| Enterprise Value to Net Income | -9 |
| Total Debt to Enterprise | 0.08 |
| Debt to Equity | 0.17 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 5, 2026
EPS Estimate
$-0.09
Average shareholder expectationRevenue Estimate
$47.31 M
Average shareholder expectationNext Earnings Call
Expected Date
November 4, 2026
EPS Estimate
$-0.07
Average shareholder expectationRevenue Estimate
$53.05 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.09%▼ 63.74% |
|---|---|
| Total Invested | $594,066▼ 99.84% |
| Investors Holding | 14▼ 142.00% |
ESG Score
No data
About Cytek BioSciences Inc
2,021 employees